The FDA on Jan. 16 approved Takeda’s HyQvia as a maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP), a progressive autoimmune disease that causes weakness over time. The subcutaneous immune globulin infusion can be administered every two, three or four weeks, and at-home use is an option for some patients. This is HyQvia’s second indication — it was first approved in 2014 for the treatment of primary immunodeficiency (PI). For this indication, it currently holds covered or better status for 95% of all insured lives under the medical benefit. 21% of lives have covered access without utilization management restrictions.
SOURCE: MMIT Analytics, as of 1/17/24